Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules of Dr. Reddy's Laboratories Limited Under Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01149954
Recruitment Status : Completed
First Posted : June 24, 2010
Last Update Posted : June 29, 2010
Sponsor:
Information provided by:
Dr. Reddy's Laboratories Limited

Brief Summary:
The purpose of this study is to compare the rate and extent of absorption of ibuprofen 200 mg gelcaps (test) versus Advil liquigels (reference) administered as 1 x 200 mg gelcap under fed conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Ibuprofen Phase 1

Detailed Description:
Randomized, 2-way crossover, bioequivalence study of Ibuprofen 200 mg gel capsules and Advil liquigels 200 mg gel caps administered as 1 x 200 mg gel capsule in healthy subjects under fed conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, 2-way Crossover, Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules and Advil Liquigels 200 mg Gel Capsules Administered as 1 x 200 mg Gel Capsules in Healthy Subjects Under Fed Conditions
Study Start Date : January 2003
Actual Primary Completion Date : January 2003
Actual Study Completion Date : January 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malnutrition

Arm Intervention/treatment
Experimental: Ibuprofen
Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
Drug: Ibuprofen
Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Other Name: Advil liquigels 200 mg gel capsules

Active Comparator: Advil
Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
Drug: Ibuprofen
Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Other Name: Advil liquigels 200 mg gel capsules




Primary Outcome Measures :
  1. Bioequivalence based on Cmax and AUC parameters [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects will be females and/or males, smokers and/or non-smokers, 18 years of age and older.

Exclusion Criteria:

  • Clinically significant illnesses within 4 weeks of the administration of study medication.
  • Clinically significant surgery within 4 weeks prior to the administration of the study medication.
  • Any clinically significant abnormality found during medical screening.
  • Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study.
  • Abnormal laboratory tests judged clinically significant.
  • Positive urine drug screen at screening.
  • Positive testing for hepatitis B, hepatitis C or at screening.
  • ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or over 90 mmHg; or heart rate less than 50 or over 100 bpm) at screening.
  • Subjects with Body Mass Index (BMI) ≥30.0.
  • History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than fourteen units of alcohol per week (1 unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).
  • History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit.
  • History of allergic reactions to ibuprofen or other NSAIDs (e.g. aspirin, diclofenac,diflunisal, etodolac, ketoprofen, fenoprofen, floctafenine, flurbiprofen, indomethacin,ketorolac, mefenamic acid, nabumetone, naproxen, oxaprozin, piroxicam, salsalate,sulindac, tenoxicam, tiaprofenic acid and tolmetin).
  • History of allergic reactions to heparin.
  • Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin,ketoconazole, Mono Amine Oxadise (MAO) inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior to administration of the study medication.
  • Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
  • History or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug.
  • Any history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
  • Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins, garlic as supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the medical subinvestigator, contraindicates the subject's participation in this study.
  • Subjects who have had a depot injection or an implant of any drug 3 months prior to administration of study medication.
  • Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to administration of the study medication as follows:

    • less than 300 mL of whole blood within 30 days or
    • 300 mL to 500 mL of whole blood within 45 days or
    • more than 500 mL of whole blood within 56 days.
  • Subjects who have consumed food or beverages containing grapefruit (e.g. fresh, canned,or frozen) within 7 days prior to administration of the study medication.
  • Subjects with history or known presence of active peptic ulcer or heartburn.
  • Subjects with history or known presence of gastrointestinal bleeding.
  • Subjects with history or known presence of bronchospastic reactivity (e.g. asthma).

For females:

  • Breast-feeding subjects.
  • Positive urine pregnancy test at screening (performed on all females).
  • Female subjects of childbearing potential who have had unprotected sexual intercourse with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for at least 6 months) within 14 days prior to study drug administration. The acceptable methods of contraception are:

    • Condom + spermicide
    • Diaphragm + spermicide
    • Intrauterine contraceptive device (placed at least 4 weeks prior to study drug administration).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01149954


Locations
Layout table for location information
Canada
Anaphann Inc.
Quebec, Canada, GIV 2K8
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
Layout table for investigator information
Study Director: Benoit Girard, MD Anapharm

Layout table for additonal information
Responsible Party: Dr. Rama Krishna Bangaru / Assistant Manager, Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier: NCT01149954     History of Changes
Other Study ID Numbers: 02280
First Posted: June 24, 2010    Key Record Dates
Last Update Posted: June 29, 2010
Last Verified: June 2010
Keywords provided by Dr. Reddy's Laboratories Limited:
Bioequivalence
Crossover
Ibuprofen
Additional relevant MeSH terms:
Layout table for MeSH terms
Ibuprofen
Malnutrition
Nutrition Disorders
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action